Index NDX, S&P 500
P/E 14.49
EPS (ttm) 4.50
Insider Own 0.10%
Shs Outstand 1.25B
Perf Week -1.35%
Market Cap 81.39B
Forward P/E 8.93
EPS next Y 7.31
Insider Trans -2.00%
Shs Float 1.25B
Perf Month -9.86%
Income 5.66B
PEG 2.70
EPS next Q 1.69
Inst Own 85.82%
Short Float 1.70%
Perf Quarter -18.65%
Sales 27.06B
P/S 3.01
EPS this Y -41.81%
Inst Trans 0.85%
Short Ratio 2.94
Perf Half Y -16.48%
Book/sh 18.33
P/B 3.56
EPS next Y 86.90%
ROA 9.04%
Short Interest 21.18M
Perf Year -23.74%
Cash/sh 6.70
P/C 9.75
EPS next 5Y 5.38%
ROE 25.71%
52W Range 65.90 - 87.86
Perf YTD -19.43%
Dividend Est. 3.14 (4.82%)
P/FCF 10.97
EPS past 5Y 1.55%
ROI 12.16%
52W High -25.72%
Beta 0.22
Dividend TTM 3.02 (4.63%)
Quick Ratio 1.27
Sales past 5Y 4.16%
Gross Margin 77.94%
52W Low -0.96%
ATR (14) 1.11
Dividend Ex-Date Mar 14, 2024
Current Ratio 1.43
EPS Y/Y TTM 23.94%
Oper. Margin 33.96%
RSI (14) 24.70
Volatility 1.76% 1.52%
Employees 18000
Debt/Eq 1.12
Sales Y/Y TTM -0.10%
Profit Margin 20.93%
Recom 2.22
Target Price 84.91
Option/Short Yes / Yes
LT Debt/Eq 1.04
EPS Q/Q -12.32%
Payout 66.62%
Rel Volume 2.10
Prev Close 67.08
Sales Surprise 5.17%
EPS Surprise 11.60%
Sales Q/Q -2.75%
Earnings Apr 25 AMC
Avg Volume 7.21M
Price 65.27
SMA20 -5.50%
SMA50 -8.84%
SMA200 -14.65%
Trades
Volume 15,131,102
Change -2.70%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-24-24 Upgrade
HSBC Securities
Reduce → Hold
$69
Feb-22-24 Downgrade
Truist
Buy → Hold
$91 → $82
Nov-09-23 Initiated
Deutsche Bank
Hold
$75
Sep-08-23 Upgrade
BofA Securities
Neutral → Buy
$88 → $95
Sep-06-23 Initiated
HSBC Securities
Reduce
$71
Jul-24-23 Reiterated
Barclays
Equal Weight
$81 → $80
May-16-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$90 → $100
Apr-28-23 Resumed
Piper Sandler
Overweight
$105
Jan-03-23 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$87
Dec-13-22 Resumed
BofA Securities
Neutral
$85
Dec-09-22 Downgrade
DZ Bank
Buy → Hold
$90
Oct-31-22 Upgrade
Barclays
Underweight → Equal Weight
$60 → $76
Oct-28-22 Upgrade
Truist
Hold → Buy
$76 → $91
Oct-28-22 Upgrade
Piper Sandler
Neutral → Overweight
$79 → $96
Oct-28-22 Reiterated
Wells Fargo
Equal Weight
$74 → $75
Oct-28-22 Reiterated
RBC Capital Mkts
Outperform
$79 → $82
Oct-28-22 Reiterated
JP Morgan
Overweight
$80 → $87
Oct-28-22 Reiterated
Jefferies
Buy
$78 → $86
Oct-28-22 Reiterated
Cowen
Outperform
$75 → $80
Oct-28-22 Reiterated
BMO Capital Markets
Market Perform
$63 → $72
Show Previous Ratings
Today 09:45PM
06:00PM
05:49PM
05:41PM
05:15PM
04:59PM
Loading…
04:59PM
04:50PM
04:40PM
(Investor's Business Daily)
04:14PM
(Associated Press Finance)
04:11PM
04:07PM
(Investor's Business Daily)
04:02PM
04:02PM
Apr-22-24 01:57PM
09:16AM
05:50PM
Loading…
Apr-19-24 05:50PM
Apr-18-24 06:33PM
06:00PM
01:45PM
10:01AM
Apr-17-24 02:03AM
Apr-16-24 09:00AM
Apr-15-24 08:00AM
01:06AM
12:22AM
Apr-12-24 06:00PM
Apr-11-24 09:15AM
Apr-10-24 06:09PM
Apr-09-24 06:15PM
02:40PM
07:37AM
Loading…
07:37AM
Apr-08-24 04:05PM
Apr-06-24 06:49AM
Apr-05-24 08:30AM
Apr-03-24 09:00AM
Apr-02-24 06:00PM
09:15AM
Mar-28-24 08:30AM
07:00AM
06:45AM
06:45AM
Mar-26-24 09:15AM
05:15AM
Mar-25-24 06:00PM
Mar-22-24 09:18AM
Mar-20-24 09:00AM
Mar-19-24 06:00PM
09:05AM
Mar-18-24 07:29PM
08:00AM
(Investor's Business Daily)
Mar-17-24 05:20PM
08:50AM
08:15AM
Mar-15-24 06:00AM
Mar-14-24 09:38AM
Mar-13-24 06:00PM
07:03AM
Mar-12-24 08:45AM
Mar-11-24 08:24AM
08:02AM
Mar-10-24 06:35AM
Mar-07-24 05:50PM
11:31AM
07:59AM
07:15AM
Mar-06-24 04:30PM
10:25AM
09:00AM
08:00AM
06:15AM
Mar-05-24 04:35PM
04:30PM
08:45AM
07:00AM
02:56AM
Mar-01-24 05:50PM
Feb-29-24 08:30AM
06:01AM
Feb-28-24 05:15PM
Feb-27-24 10:00AM
Feb-26-24 04:05PM
08:30AM
08:15AM
Feb-24-24 07:04AM
05:52AM
Feb-22-24 09:00AM
Feb-21-24 04:37PM
Feb-20-24 04:05PM
09:25AM
07:00AM
Feb-19-24 01:46PM
Feb-16-24 05:43AM
Feb-15-24 06:37PM
04:13PM
Feb-13-24 09:24AM
08:30AM
Feb-12-24 04:44PM
04:15PM
(Investor's Business Daily)
01:27PM
12:27PM
(The Wall Street Journal)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Parsey Merdad Chief Medical Officer Apr 01 '24 Sale 72.96 2,000 145,920 96,304 Apr 02 06:38 PM Parsey Merdad Chief Medical Officer Feb 29 '24 Sale 72.74 8,230 598,624 92,706 Feb 29 06:35 PM Parsey Merdad Chief Medical Officer Feb 28 '24 Sale 73.18 2,000 146,360 100,936 Feb 29 06:35 PM GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM GILEAD SCIENCES, INC. 10% Owner Jan 29 '24 Buy 21.00 15,238,095 319,999,995 30,061,124 Jan 31 05:00 PM Dickinson Andrew D Chief Financial Officer Jan 16 '24 Sale 85.78 5,000 428,900 101,534 Jan 17 06:01 PM Mercier Johanna Chief Commercial Officer Jan 09 '24 Sale 85.23 8,242 702,466 82,729 Jan 10 03:58 PM Dickinson Andrew D Chief Financial Officer Oct 17 '23 Sale 80.00 5,000 400,017 104,003 Oct 18 04:31 PM Parsey Merdad Chief Medical Officer Sep 12 '23 Sale 76.99 1,501 115,562 70,130 Sep 13 06:50 PM Dickinson Andrew D Chief Financial Officer Jul 20 '23 Sale 80.00 5,000 400,000 107,587 Jul 21 05:30 PM GILEAD SCIENCES, INC. 10% Owner Jun 28 '23 Buy 19.26 1,010,000 19,452,600 14,823,029 Jun 30 03:12 PM GILEAD SCIENCES, INC. 10% Owner Jun 27 '23 Buy 3.75 2,930,870 10,990,762 16,635,286 Jun 28 05:17 PM Parsey Merdad Chief Medical Officer Jun 13 '23 Sale 76.90 1,485 114,197 29,402 Jun 14 05:48 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite